Period after initial PTA (months) | 7–72 (32) | 0–88 (27) | 0–42 (7.8) | 30–99 (55) |
Period after latest PTA (months) | 0–12 (3) | 0–17 (6.5) | 0 | 2–10 (5.3) |
T bilirubin (mg/dl) | 0.5–4.1 (2.0) | 1.0–15.9 (4.3) | 1.7–26.3 (7.9) | 8–29 (19.3) |
Alkaline phosphatase (IU/l) | 146–1485 (553) | 248–1065 (417) | 229–787 (470) | 448–965 (625) |
γ-GTP (IU/l) | 51–952 (268) | 34–253 (110) | 53–649 (267) | 111–494 (309) |
Abdominal pain | 4/10 (40%) | 6/11 (55%) | 4/8 (50%) | 3/3 (100%) |
Pancreatitis | 0/10 (0%) | 3/11 (27%) | 0/8 (0%) | 0/3 (0%) |
Liver abscess | 5/10 (50%) | 2/11 (18%) | 0/8 (0%) | 0/3 (0%) |
Gallstone | 2/10 (20%) | 10/10 (100%) | 3/8 (40%) | 0/2 (0%) |
“Haemobilia sign” | 1/10 (10%) | 0/11 (0%) | 8/8 (100%) | 1/2 (50%) |
Biliary strictures | 9/10 (90%) | 2/11 (18%) | 1/8 (13%) | 1/3 (33%) |
Type of PTA (PEIT/PMCT/RFA) | 10/2/1 | 9/1/2 | 8/0/0 | 3/0/0 |
History of TAE | 8/10 (80%) | 6/11 (55%) | 2/8 (25%) | 1/3 (33%) |
Size of HCC (cm) | 0–8.5 (2.9) | 0–7.5 (3.2) | 1.5–6 (3.4) | 2 |
PVTT | 1/10 (10%) | 1/11 (9%) | 2/8 (25%) | 1/3 (33%) |
Additional therapy | None | None | TAE 1 | Surgery for HCC 2, PTA 1 |
Immediate prognosis | | | | |
Recovered | 10/10 (100%) | 11/11 (100%) | 6/8 (75%) | 3/3 (100%) |
Died | | | 2/8 (25%) | |